Best Medical Stocks To Watch For 2019

tags:HEES,ORAN,TUP,NFBK,RARE,SERV,

VentriPoint Diagnostics states, "It's time for the whole heart." The medical device company has redesigned VMS to meet the demands of every market. Preparing to move beyond the Right and Left Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI. All from the convenience of 2D Ultrasound. The Cleveland Clinic quipped, "The VMS will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI." The Cleveland Clinic is the second-highest rated hospital in the United States.

Rapid measurement of right ventricular volume and function in patients with congenital heart disease is the foundation of Knowledge Based Reconstruction. The same technique also measures left ventricular volume. The measurements are made from either three-dimensional (3-D) ultrasound or magnetic resonance images (MRI). Physician monitoring detects when the heart begins to fail. The primary advantage to Knowledge Based Reconstruction is that it will help pediatricians choose the best timing for surgery. The product can also be used to evaluate how well patients respond to treatment.

Best Medical Stocks To Watch For 2019: H&E Equipment Services Inc.(HEES)

Advisors' Opinion:

• [By Shane Hupp]

  H&E Equipment Services (NASDAQ: HEES) and WillScot (NASDAQ:WSC) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

• [By Joseph Griffin]

  SG Americas Securities LLC trimmed its holdings in shares of H&E Equipment Services, Inc. (NASDAQ:HEES) by 42.9% in the 1st quarter, Holdings Channel reports. The firm owned 4,026 shares of the industrial products company’s stock after selling 3,030 shares during the quarter. SG Americas Securities LLC’s holdings in H&E Equipment Services were worth $155,000 at the end of the most recent quarter.

• [By Peter Graham]

  A long term performance chart shows shares of United Rentals giving a similar performance but also pulling away from small cap peer H&E Equipment Services, Inc (NASDAQ: HEES):

• [By Logan Wallace]

  H&E Equipment Services (NASDAQ: HEES) and WillScot (NASDAQ:WSC) are both small-cap industrial products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Best Medical Stocks To Watch For 2019: Orange(ORAN)

Advisors' Opinion:

• [By Shane Hupp]

  Bank of America Corp DE boosted its holdings in Orange SA (NYSE:ORAN) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,916,094 shares of the technology company’s stock after purchasing an additional 330,125 shares during the quarter. Bank of America Corp DE owned approximately 0.22% of Orange worth $98,621,000 at the end of the most recent quarter.

• [By Anders Bylund, Timothy Green, and Dan Caplinger]

  The trick is to separate high-quality income generators from their lower-quality peers. So we asked a few of your fellow investors here at The Motley Fool to share their best dividend ideas with yields of 4% or more. Read on to see why they recommend tech titan International Business Machines (NYSE:IBM), international telecom Orange (NYSE:ORAN), and energy giant ExxonMobil (NYSE:XOM).

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Orange (ORAN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  ValuEngine downgraded shares of Orange (NYSE:ORAN) from a buy rating to a hold rating in a research report released on Monday morning.

  ORAN has been the topic of several other reports. Zacks Investment Research cut Orange from a hold rating to a sell rating in a research report on Wednesday, April 25th. BNP Paribas raised Orange from an underperform rating to a neutral rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Orange has a consensus rating of Hold and an average price target of $19.00.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Orange (ORAN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Medical Stocks To Watch For 2019: Tupperware Brands Corporation(TUP)

Advisors' Opinion:

• [By Logan Wallace]

  LSV Asset Management increased its stake in shares of Tupperware Brands (NYSE:TUP) by 26.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 99,275 shares of the company’s stock after purchasing an additional 20,700 shares during the period. LSV Asset Management owned approximately 0.19% of Tupperware Brands worth $4,802,000 at the end of the most recent reporting period.

• [By Logan Wallace]

  LPL Financial LLC increased its position in shares of Tupperware Brands Co. (NYSE:TUP) by 9.5% during the 1st quarter, HoldingsChannel reports. The fund owned 102,259 shares of the company’s stock after purchasing an additional 8,848 shares during the period. LPL Financial LLC’s holdings in Tupperware Brands were worth $4,947,000 at the end of the most recent reporting period.

• [By Shane Hupp]

  Allianz Asset Management GmbH trimmed its holdings in shares of Tupperware Brands Co. (NYSE:TUP) by 71.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,109 shares of the company’s stock after selling 51,757 shares during the quarter. Allianz Asset Management GmbH’s holdings in Tupperware Brands were worth $1,021,000 as of its most recent SEC filing.

Best Medical Stocks To Watch For 2019: Northfield Bancorp Inc.(NFBK)

Advisors' Opinion:

• [By Stephan Byrd]

  Media coverage about Northfield Bancorp (NASDAQ:NFBK) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Northfield Bancorp earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the bank an impact score of 46.1080127060523 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

• [By Shane Hupp]

  Shares of Northfield Bancorp Inc. (NASDAQ:NFBK) have received a consensus recommendation of “Hold” from the eight brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $17.50.

• [By Logan Wallace]

  Northfield Bancorp Inc. (NASDAQ:NFBK) EVP Kenneth J. Doherty sold 2,449 shares of the firm’s stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $16.19, for a total value of $39,649.31. Following the completion of the transaction, the executive vice president now owns 198,742 shares in the company, valued at $3,217,632.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

• [By Logan Wallace]

  Shares of Northfield Bancorp Inc (NASDAQ:NFBK) have earned a consensus rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $17.25.

• [By Logan Wallace]

  These are some of the news stories that may have impacted Accern Sentiment’s scoring:

  Get Northfield Bancorp alerts: Head-To-Head Contrast: Northfield Bancorp (NFBK) & The Competition (americanbankingnews.com) Northfield Bancorp (NFBK) and Its Competitors Critical Survey (americanbankingnews.com) Head to Head Survey: Northfield Bancorp (NFBK) versus The Competition (americanbankingnews.com) Northfield Bancorp (NFBK) Stock Rating Lowered by BidaskClub (americanbankingnews.com) Northfield Bancorp (NFBK) & Its Rivals Head to Head Analysis (americanbankingnews.com)

  Shares of Northfield Bancorp opened at $15.96 on Thursday, MarketBeat reports. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.71. Northfield Bancorp has a twelve month low of $15.88 and a twelve month high of $15.92. The firm has a market capitalization of $777.27 million, a P/E ratio of 21.86, a price-to-earnings-growth ratio of 2.37 and a beta of 0.35.

• [By Joseph Griffin]

  BidaskClub upgraded shares of Northfield Bancorp (NASDAQ:NFBK) from a hold rating to a buy rating in a research note released on Saturday morning.

  Other equities analysts also recently issued reports about the stock. TheStreet raised shares of Northfield Bancorp from a c+ rating to a b rating in a research note on Thursday, April 26th. ValuEngine downgraded shares of Northfield Bancorp from a hold rating to a sell rating in a research note on Tuesday, June 12th. Zacks Investment Research downgraded shares of Northfield Bancorp from a buy rating to a hold rating in a research note on Thursday, May 17th. Finally, Keefe, Bruyette & Woods reaffirmed a hold rating and set a $18.50 target price on shares of Northfield Bancorp in a research note on Tuesday, February 27th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Northfield Bancorp presently has an average rating of Hold and an average price target of $17.60.

Best Medical Stocks To Watch For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors' Opinion:

• [By Shane Hupp]

  Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

• [By Joseph Griffin]

  BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

  A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

• [By Shane Hupp]

  These are some of the media headlines that may have effected Accern’s scoring:

  Get Ultragenyx Pharmaceutical alerts: Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

  A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

• [By Shane Hupp]

  Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

• [By Chris Lange]

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Medical Stocks To Watch For 2019: ServiceMaster Global Holdings, Inc.(SERV)

Advisors' Opinion:

• [By Rich Smith]

  The clock reads 11:45 AM EDT, and shares of ServiceMaster Global Holdings (NYSE:SERV) are either down 34% or maybe down less than 2%, depending on whom you ask. Google Finance says the former, while Yahoo! Finance reports the latter. 

• [By Rich Smith]

  That's how ServiceMaster CEO Nik Varty describes the future of his own company, ServiceMaster Global Holdings (NYSE:SERV), with its stable of brands like Terminix, Furniture Medic, and Merry Maids. It's also the future he sees for the company ServiceMaster just spun off: Frontdoor (UNKNOWN:UNKNOWN), which inherited probably the company's best-known brand, American Home Shield (AHS). And already, some analysts on Wall Street are nodding their heads.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Servicemaster Global (SERV)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  Servicemaster Global Holdings Inc (NYSE:SERV) hit a new 52-week high and low during trading on Thursday . The company traded as low as $59.70 and last traded at $59.03, with a volume of 15886 shares trading hands. The stock had previously closed at $59.62.

• [By Max Byerly]

  ServiceMaster (NYSE:SERV)’s share price reached a new 52-week high and low during trading on Tuesday . The company traded as low as $55.63 and last traded at $54.76, with a volume of 207508 shares traded. The stock had previously closed at $55.35.